Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MR-100A-01, 100A-01
MR-100A-01 (low-dose estrogen weekly contraceptive patch) · 1 trial · 1 indication
The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years times 100
| Arm | Type | Description |
|---|---|---|
| MR-100A-01 | EXPERIMENTAL | MR-100A-01 is a transdermal delivery system designed to deliver daily hormone exposure of Norelgestromin and Ethinyl Estradiol |
| Name | Type | Description |
|---|---|---|
| MR-100A-01 | DRUG | Transdermal contraceptive delivery system |
Inclusion Criteria: 1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least 16 years of age with no upper age limit. Post-menarcheal female subjects who are at risk of pregnancy, and \<18 years are eligible provided that: 1. Applicable national, state, and loca...
MR-100A-01 is an investigational low-dose estrogen weekly contraceptive patch developed by Viatris Inc. (ticker VTRS). It is a small molecule product in Phase 3 development for contraception. The patch is designed to be applied weekly, and it is being studied in healthy women aged 16 years and older.
MR-100A-01 is being developed for contraception. It is a weekly contraceptive patch containing a low dose of estrogen. The Phase 3 trial enrolled approximately 1,200 healthy women and evaluated use for up to 13 cycles. It is not approved for any indication and remains investigational.
MR-100A-01 is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor of the Phase 3 clinical trial evaluating the contraceptive patch. No other developer or partner is identified for this asset.
MR-100A-01 is in Phase 3 development. One Phase 3 trial has been completed, and no active trials are ongoing. The completed study, NCT05139121, enrolled 1,319 healthy female participants aged 16 years and older in the United States, Canada, and Puerto Rico.
MR-100A-01 has been studied in one Phase 3 trial, NCT05139121, titled Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles. The trial is completed, enrolled 1,319 participants, and was conducted in the United States, Canada, and Puerto Rico.
Yes, MR-100A-01 is also known as 100A-01. Both names refer to the same investigational low-dose estrogen weekly contraceptive patch developed by Viatris Inc. (ticker VTRS). The asset is in Phase 3 development for contraception.